BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35172861)

  • 1. CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype.
    Mancarella S; Serino G; Gigante I; Cigliano A; Ribback S; Sanese P; Grossi V; Simone C; Armentano R; Evert M; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2022 Feb; 41(1):65. PubMed ID: 35172861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
    Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
    Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression.
    Mancarella S; Serino G; Coletta S; Armentano R; Dituri F; Ardito F; Ruzzenente A; Fabregat I; Giannelli G
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
    Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Silencing of
    Montanari M; Carbone MR; Coppola L; Giuliano M; Arpino G; Lauria R; Nardone A; Leccia F; Trivedi MV; Garbi C; Bianco R; Avvedimento EV; De Placido S; Veneziani BM
    Mol Cancer Res; 2019 Feb; 17(2):628-641. PubMed ID: 30242055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Numb promotes hepatic progenitor expansion and intrahepatic cholangiocarcinoma by enhancing Notch signaling.
    Shu Y; Xu Q; Xu Y; Tao Q; Shao M; Cao X; Chen Y; Wu Z; Chen M; Zhou Y; Zhou P; Shi Y; Bu H
    Cell Death Dis; 2021 Oct; 12(11):966. PubMed ID: 34667161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
    Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
    Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.
    Lu X; Peng B; Chen G; Pes MG; Ribback S; Ament C; Xu H; Pal R; Rodrigues PM; Banales JM; Evert M; Calvisi DF; Chen X; Fan B; Wang J
    Am J Pathol; 2021 Sep; 191(9):1651-1667. PubMed ID: 34129844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis.
    Yamaoka R; Ishii T; Kawai T; Yasuchika K; Miyauchi Y; Kojima H; Katayama H; Ogiso S; Fukumitsu K; Uemoto S
    J Surg Oncol; 2018 Sep; 118(4):664-674. PubMed ID: 30196535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant fucosylation sustains the NOTCH and EGFR/NF-κB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
    Ament CE; Steinmann S; Evert K; Pes GM; Ribback S; Gigante I; Pizzuto E; Banales JM; Rodrigues PM; Olaizola P; Wang H; Giannelli G; Chen X; Evert M; Calvisi DF
    Hepatology; 2023 Dec; 78(6):1742-1754. PubMed ID: 36789652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma.
    Cigliano A; Pilo MG; Mela M; Ribback S; Dombrowski F; Pes GM; Cossu A; Evert M; Calvisi DF; Utpatel K
    Medicina (Kaunas); 2019 Dec; 56(1):. PubMed ID: 31861475
    [No Abstract]   [Full Text] [Related]  

  • 13. Notch1 Drives the Formation and Proliferation of Intrahepatic Cholangiocarcinoma.
    Guo J; Fu W; Xiang M; Zhang Y; Zhou K; Xu CR; Li L; Kuang D; Ye F
    Curr Med Sci; 2019 Dec; 39(6):929-937. PubMed ID: 31845224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expressions of HMGA2 and Thy1 in extrahepatic cholangiocarcinoma and their clinicopathological significances.
    Liu R; Yang Z; Huang S; Li D; Zou Q; Yuan Y
    Surg Oncol; 2019 Jun; 29():41-47. PubMed ID: 31196492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway.
    Li JH; Zhu XX; Li FX; Huang CS; Huang XT; Wang JQ; Gao ZX; Li SJ; Xu QC; Zhao W; Yin XY
    J Exp Clin Cancer Res; 2019 Nov; 38(1):476. PubMed ID: 31775892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 17. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
    Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
    PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of Notch1 expression in the migration of intrahepatic cholangiocarcinoma.
    Zhou Q; Wang Y; Peng B; Liang L; Li J
    BMC Cancer; 2013 May; 13():244. PubMed ID: 23688168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
    J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unveiling the role of HP1α-HDAC1-STAT1 axis as a therapeutic target for HP1α-positive intrahepatic cholangiocarcinoma.
    Xiong F; Wang D; Xiong W; Wang X; Huang WH; Wu GH; Liu WZ; Wang Q; Chen JS; Kuai YY; Wang B; Chen YJ
    J Exp Clin Cancer Res; 2024 May; 43(1):152. PubMed ID: 38812060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.